Novartis adds to case for US pediatric psoriasis indication

29 October 2020
2020_novartis_big

Swiss pharma major Novartis (NOVN: VX) has strengthened its case for a US Food and Drug Administration (FDA) approval of Cosentyx (secukinumab) in pediatric psoriasis.

The Basel-based company has presented two pivotal international Phase III studies, which show Cosentyx provides fast and strong skin clearance and significant improvement in quality of life in children and adolescents aged six to 18 years with moderate-to-severe plaque psoriasis.

Moderate-to-severe psoriasis affects more than 350,000 children worldwide, with one third of cases beginning in childhood and, of these, the onset is most common during adolescence.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology